Table 3. Total number and value of indirect payments from pharmaceutical companies as a proportion of all indirect payments (2012–2018).
| APPG category (in bold) and name** | Total indirect payments—n | Total indirect payments with value—n | Total value of indirect payments†—£ | Total indirect payments from pharmaceutical companies—n (%) | Total indirect payments from pharmaceutical companies with value—n (%) | Total value of indirect payments from pharmaceutical companies—£ (%) |
|---|---|---|---|---|---|---|
| Health of a collective | 8 | 4 | 87,918.65 | 8 (100) | 4 (100) | 52,307.09 (59.49) |
| Alcohol Harm | 5 | 1 | 16,695.53 | 5 (100) | 1 (100) | 16,695.53 (100) |
| Women’s Health | 3 | 3 | 71,223.12 | 3 (100) | 3 (100) | 35,611.56 (50) |
| Medical speciality or specialist area | 8 | 1 | 18,285.53 | 5 (62.5) | 1 (100) | 9,142.77 (50) |
| Sexual and Reproductive Health | 1 | 1 | 18,285.53 | 1 (100) | 1 (100) | 9,142.77 (50) |
| Liver Health | 4 | 0 | - | 4 (100) | 0 | - |
| Physical or mental health conditions | 67 | 32 | 709,189.71 | 26 (38.81) | 13 (40.63) | 291,248.00 (41.07) |
| Sickle Cell and Thalassaemia | 10 | 6 | 117,839.30 | 10 (100) | 6 (100) | 117,839.30 (100) |
| Thrombosis | 8 | 4 | 162,878.87 | 7 (87.5) | 3 (75) | 85,330.28 (52.39) |
| Tuberculosis | 2 | 0 | - | 1 (50) | 0 | - |
| Obesity | 3 | 1 | 68,296.84 | 1 (33.33) | 1 (100) | 45,531.23 (66.67) |
| Atrial Fibrillation | 7 | 3 | 48,185.12 | 7 (100) | 3 (100) | 42,547.19 (88.3) |
| Total received by the APPGs | 43 | 19 | 503,404.31 | 39 (90.7) | 18 (94.74) | 352,697.86 (70.06) |
* Bold text indicated the category of the APPG to allow us to present the total number and value of payments received by each category as well as each APPG receiving industry payments.
* Values were not provided in the archived Register, therefore these values are for payments registered in July 2015 onwards.